Medicenna Therapeutics Corp Stock Analysis
| MDNA Stock | CAD 1.72 0.06 3.37% |
Medicenna Therapeutics Corp is overvalued with Real Value of 1.55 and Hype Value of 1.72. The main objective of Medicenna Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Medicenna Therapeutics Corp is worth, separate from its market price. There are two main types of Medicenna Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Medicenna Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Medicenna Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Medicenna Therapeutics stock is traded in Canada on Toronto Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Canada. Medicenna Therapeutics is usually not traded on Canada Day, Civic Holiday, Labour Day, Thanksgiving Day, Christmas Day, Boxing Day, New Year 's Day, Family Day, Good Friday, Victoria Day. Medicenna Stock trading window is adjusted to America/Toronto timezone.
Medicenna |
Medicenna Stock Analysis Notes
About 22.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.38. Medicenna Therapeutics last dividend was issued on the 3rd of March 2017. The entity had 1:14 split on the 3rd of March 2017. Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines and Superkines for the treatment of cancer. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. MEDICENNA THERAPEUTICS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 7 people. To find out more about Medicenna Therapeutics Corp contact the company at 416 648 5555 or learn more at https://www.medicenna.com.Medicenna Therapeutics Investment Alerts
| Medicenna Therapeutics generated a negative expected return over the last 90 days | |
| Medicenna Therapeutics has high historical volatility and very poor performance | |
| Medicenna Therapeutics may become a speculative penny stock | |
| Medicenna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (25.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Medicenna Therapeutics Corp has accumulated about 33.6 M in cash with (16.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Medicennas MDNA11 Drug Shows 30 percent Response Rate, Strong Results in Cancer Trial MDNAF Stock News - StockTitan |
Medicenna Largest EPS Surprises
Earnings surprises can significantly impact Medicenna Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2024-08-02 | 2024-06-30 | -0.06 | -0.05 | 0.01 | 16 | ||
2022-08-15 | 2022-06-30 | -0.08 | -0.07 | 0.01 | 12 |
Medicenna Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 139.12 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medicenna Therapeutics's market, we take the total number of its shares issued and multiply it by Medicenna Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Medicenna Profitablity
Medicenna Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Medicenna Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Medicenna Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Medicenna Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Medicenna Therapeutics' profitability requires more research than a typical breakdown of Medicenna Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.33) | (1.40) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (1.33) | (1.40) | |
| Return On Equity | (4.91) | (4.66) |
Management Efficiency
Medicenna Therapeutics has return on total asset (ROA) of (0.328) % which means that it has lost $0.328 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0543) %, meaning that it generated substantial loss on money invested by shareholders. Medicenna Therapeutics' management efficiency ratios could be used to measure how well Medicenna Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to drop to -1.4. In addition to that, Return On Capital Employed is likely to grow to -1.15. At this time, Medicenna Therapeutics' Net Tangible Assets are very stable compared to the past year. As of the 2nd of December 2024, Non Current Assets Total is likely to grow to about 87.7 K, while Total Assets are likely to drop about 19 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.07 | 0.07 | |
| Tangible Book Value Per Share | 0.07 | 0.07 | |
| Enterprise Value Over EBITDA | (5.84) | (6.13) | |
| Price Book Value Ratio | 24.28 | 25.50 | |
| Enterprise Value Multiple | (5.84) | (6.13) | |
| Price Fair Value | 24.28 | 25.50 | |
| Enterprise Value | 21 M | 20 M |
Leadership effectiveness at Medicenna Therapeutics Corp is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 1.189 | Return On Assets (0.33) | Return On Equity (1.05) |
Technical Drivers
As of the 2nd of December, Medicenna Therapeutics secures the Risk Adjusted Performance of (0.01), standard deviation of 5.3, and Mean Deviation of 3.97. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medicenna Therapeutics, as well as the relationship between them.Medicenna Therapeutics Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Medicenna Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Medicenna Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Medicenna Therapeutics Outstanding Bonds
Medicenna Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Medicenna Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Medicenna bonds can be classified according to their maturity, which is the date when Medicenna Therapeutics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Medicenna Therapeutics Predictive Daily Indicators
Medicenna Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Medicenna Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Medicenna Therapeutics Forecast Models
Medicenna Therapeutics' time-series forecasting models are one of many Medicenna Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Medicenna Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Medicenna Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Medicenna Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Medicenna shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Medicenna Therapeutics. By using and applying Medicenna Stock analysis, traders can create a robust methodology for identifying Medicenna entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Medicenna Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Transaction History Now
Transaction HistoryView history of all your transactions and understand their impact on performance |
| All Next | Launch Module |
Other Information on Investing in Medicenna Stock
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.